XML 59 R46.htm IDEA: XBRL DOCUMENT v3.25.4
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
12 Months Ended
Nov. 05, 2025
May 07, 2025
Jan. 02, 2024
Apr. 26, 2021
Apr. 17, 2020
Jan. 02, 2019
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2020
Collaborations with Third Parties                    
First milestone payment     $ 100,000              
Time required to pay cash portion     15 days              
Second milestone payment     $ 25,000              
Total Revenues             $ 403,135 $ 332,314 $ 116,334  
Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received                    
Collaborations with Third Parties                    
Total Revenues             148,800 205,000 37,200  
Collaboration Revenue                    
Collaborations with Third Parties                    
Total Revenues             243,566 216,589 37,999  
Minimum                    
Collaborations with Third Parties                    
Aggregate payment agreement     125,000              
Daiichi Sankyo Europe GmbH ("DSE")                    
Collaborations with Third Parties                    
Milestone payments related to total net sales achievements     $ 300,000              
Daiichi Sankyo Europe GmbH ("DSE") | Minimum | Commitment Offering                    
Collaborations with Third Parties                    
Royalties on sales     15.00%              
Daiichi Sankyo Europe GmbH ("DSE") | Maximum | Commitment Offering                    
Collaborations with Third Parties                    
Royalties on sales     25.00%              
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement                    
Collaborations with Third Parties                    
Upfront cash payment           $ 150,000        
Cash payment to the Company                   $ 150,000
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales           15.00%        
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales           25.00%        
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities                    
Collaborations with Third Parties                    
Upfront cash payment         $ 60,000          
Potential additional future payments         450,000          
Proceeds from milestone upon submission of a Japanese New Drug Application (JNDA) in the Otsuka Territory             90,000 10,000    
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Collaboration Revenue                    
Collaborations with Third Parties                    
Total Revenues             91,100 11,300 100  
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales 12.00%                  
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales 33.00%                  
Milestone payments related to total net sales achievements         310,000          
Milestone payment upon JNDA Approval in the Otsuka Territory         $ 10,000          
Daiichi Sankyo Co. Ltd | Collaborative Arrangement                    
Collaborations with Third Parties                    
Upfront cash payment       $ 30,000            
Total Revenues             2,400 100 $ 700  
Consideration cash payment       30,000            
Payment to be received upon milestone       $ 175,000            
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales       5.00%            
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales       20.00%            
Neopharm | Collaborative Arrangement                    
Collaborations with Third Parties                    
Total Revenues             0 $ 300    
Seqirus Pty Ltd | Collaborative Arrangement                    
Collaborations with Third Parties                    
Total Revenues             $ 300      
HLS Therapeutics | Collaborative Arrangement                    
Collaborations with Third Parties                    
Total Revenues   $ 1,000